EMEA calls for withdrawal of veralipride from the European market
The European Medicines Agency has called for the withdrawal from the European market of the neuroleptic, veralipride, following reports of severe side effects.
News
Five medicines recommended for European licensing
Five medicinal products, including a generic version of olanzapine, have been recommended for licensing in Europe by the main scientific committee of the European Medicines Agency (EMEA). At the same time, a proposed treatment for Crohn’s disease from Elan Pharma, was turned back.
Karolinska Institutet researchers describe enzyme linked to asthma
Researchers at the Karolinska Institutet in Sweden have described the structure of a human membrane protein that is understood to have a major influence on the development of asthma.
British universities responsible for 187 new companies
UK universities created 187 spin-off companies in the 2005-06 academic year, according to a government survey.
Newcastle University cooperates with UK peptide company
Cambridge Research Biochemicals (CRB) is preparing to investigate a new method for validating antibodies using technology based at Newcastle University and funded by one of the UK’s regional development authorities.
Pharmaceutical firms could be fined for failing to meet licensing obligations
From 7 July 2007, pharmaceutical companies holding European Community marketing authorisations could be fined at up to 5% of their Community turnover if they infringe their licensing obligations or give false information to the European Medicines Agency (EMEA).
Vivalis goes public with a listing on the Euronext Paris mid-cap section
Vivalis, a French company that has developed a stem cell technology for the manufacture of vaccines, has made an initial public offering of shares on the mid-cap section of the Euronext Paris stock exchange, worth about €46.4 million.
New medicines legislation in The Netherlands
The Netherlands has updated the rules governing the dispensing of pharmaceuticals, as well as the responsibilities of the national regulator, the Medicines Evaluation Board (MEB), in a major revision of its medicines legislation.
Silence Therapeutics set to receive up to £200 million from RNAi collaboration
Silence Therapeutics Plc, which specialises in the technology of RNA-mediated interference for the treatment of disease, has begun a three-year research and development collaboration with AstraZeneca Plc valued at up to £200 million.
EMEA and FDA to share data on paediatric trials
The European Medicines Agency and the US Food and Drug Administration have agreed to exchange information from companies about their proposed studies of paediatric medicines in order to avoid unnecessary trials involving children.